• Publications
  • Influence
Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions
A consensus meeting was held in Vienna on September 8–9, 2013, to discuss diagnostic and therapeutic challenges surrounding development of diabetes mellitus after transplantation. The InternationalExpand
  • 204
  • 34
  • Open Access
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
BACKGROUND Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in patients with tuberous sclerosis complex andExpand
  • 533
  • 27
  • Open Access
Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus
DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2 Monitoring Versus Tacrolimus) was a 6‐month, open‐label, randomized, multicenter study which used American Diabetes Association/WorldExpand
  • 500
  • 25
Enteric‐Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1‐Year Study
With the objective of enhancing upper gastrointestinal (GI) tolerability, enteric‐coated mycophenolate sodium (EC‐MPS, myfortic®, Novartis Pharma AG, Basel, Switzerland) has been developed. ThisExpand
  • 232
  • 13
  • Open Access
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial assessed the feasibilityExpand
  • 231
  • 13
The pharmacokinetics of pioglitazone in patients with impaired renal function.
AIMS To evaluate the effect of renal impairment on the pharmacokinetics and safety of pioglitazone and its metabolites M-III and M-IV with impaired renal function and normal renal function. METHODSExpand
  • 125
  • 13
Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients
The aim of this single‐center crossover substudy was to assess pharmacokinetics and pharmacodynamics [inosine 5′‐monophosphate dehydrogenase (IMPDH) activity] of enteric‐coated mycophenolate sodiumExpand
  • 106
  • 11
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
FTY720 is a novel immunomodulator to be developed for use in organ transplantation. The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics inExpand
  • 271
  • 10
  • Open Access
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients
The mutual drug‐drug interaction potential of the 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitor cerivastatin and cyclosporine (INN, ciclosporin) in kidney transplant recipientsExpand
  • 147
  • 10
Biomarkers in acute kidney injury – pathophysiological basis and clinical performance
Various biomarkers of acute kidney injury (AKI) have been discovered and characterized in the recent past. These molecules can be detected in urine or blood and signify structural damage to theExpand
  • 90
  • 10